Patent Protection for Microbial Technologies

FEMS Microbiology Letters, Vol. 364 [fnx205], 2017

NYLS Legal Studies Research Paper No. 3041221

6 Pages Posted: 25 Sep 2017 Last revised: 27 Dec 2017

See all articles by Jacob S. Sherkow

Jacob S. Sherkow

New York Law School; Columbia University - Department of Health Policy and Management; Center for Advanced Studies in Biomedical Innovation Law

Date Written: September 22, 2017

Abstract

Microbial technologies often serve as the basis of fundamental research tools in molecular biology. These presents challenges, as well as ethical, legal and social issues, concerning their patenting. This commentary presents several case studies of these issues across three major microbiological tools: CRISPR, viral vectors, and antimicrobial resistance drugs. It concludes that the development of these technologies — both scientifically and commercially — depend, in part, on the patent regime available for each.

Keywords: Patents; CRISPR; Virus; AMR; Incentives; Intellectual Property

JEL Classification: K00; K23; K41; O3; O34; D23; K11

Suggested Citation

Sherkow, Jacob S., Patent Protection for Microbial Technologies (September 22, 2017). FEMS Microbiology Letters, Vol. 364 [fnx205], 2017; NYLS Legal Studies Research Paper No. 3041221. Available at SSRN: https://ssrn.com/abstract=3041221

Jacob S. Sherkow (Contact Author)

New York Law School ( email )

185 West Broadway
New York, NY 10013
United States
212.431.2355 (Phone)

HOME PAGE: http://www.nyls.edu/faculty/faculty-profiles/faculty_profiles/jacob-s-sherkow/

Columbia University - Department of Health Policy and Management ( email )

600 West 168th Street, 6th Floor
New York, NY 10032
United States

Center for Advanced Studies in Biomedical Innovation Law ( email )

Studiestraede 6
Studiestrade 6
Copenhagen, DK-1455
Denmark

HOME PAGE: http://jura.ku.dk/cebil/staff/

Register to save articles to
your library

Register

Paper statistics

Downloads
60
rank
350,179
Abstract Views
369
PlumX Metrics